文献速递头颈部肿瘤放疗

CNG分期改善鼻咽癌预后分层并与EBV DNA相关

CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era.
PubMed 文献 · Radiother Oncol · 2025-07-19

这项前瞻性观察研究纳入1930例鼻咽癌患者,基于第7版AJCC分期重新划分为CNG I–III期。CNG各期5年总生存率分别为97.0%、91.4%和72.1%,曲线分离良好(均p<0.001),且与治疗前血浆EBV DNA分布一致,较第7、8版AJCC分期更准确区分生存。

要点

  • CNG I–III期5年OS分别为97.0%、91.4%、72.1%,曲线分离良好(均p<0.001)。
  • 第7、8版AJCC I–III期OS曲线几乎重叠,区分度不及CNG分期。
  • CNG各期EBV DNA=0比例递减、≥1000 copies/ml比例递增(p<0.001)。

核心结论

  • CNG分期较第7、8版AJCC分期更准确区分鼻咽癌生存率,且与治疗前血浆EBV DNA分布良好对应。

研究设计与样本

  • 前瞻性观察研究(NCT03529279),纳入1930例鼻咽癌患者,基于第7版AJCC分期重新划分为CNG I–III期,采用Kaplan-Meier法和log-rank检验。

主要发现

  • CNG I、II、III期5年OS分别为97.0%、91.4%、72.1%,各期生存曲线分离良好(均p<0.001)。
  • 第7版和第8版AJCC I、II、III期的OS曲线几乎重叠。
  • 治疗前血浆EBV DNA>0及≥1000 copies/ml患者中,CNG分期可见总生存及组间OS差异,而第7、8版分期未见。
  • CNG I、II、III期中EBV DNA=0比例依次为30.9%、10.8%、3.4%,EBV DNA≥1000 copies/ml比例依次为33.3%、60.0%、84.8%(p<0.001)。

关键数值与推荐

  • CNG I期:第7版I、II期及III期非T3N2;CNG II期:III期T3N2、IVA、IVB期;CNG III期:IVC期。

临床怎么用

  • 在IMRT时代可考虑用CNG分期替代第7、8版AJCC分期进行鼻咽癌预后分层,并结合治疗前血浆EBV DNA水平综合评估。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current 8th AJCC stage is less effective in differentiating survival for nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy era. This study aims to evaluate the performance of CNG (Collaborative Nasopharyngeal Carcinoma Group) stage, a clinical downstaging of NPC based on the 7th AJCC stage, in predicting prognosis compared with the AJCC stage. METHODS: In this prospective observational study (ClinicalTrials.gov Identifier: NCT03529279), 1930 patients were restaged based on the 7th stage: CNG Stage I: Stage I, II, and III-nonT3N2; CNG Stage II: III-T3N2, IVA, and IVB; CNG Stage III: IVC. Kaplan-Meier method and the log-rank test were performed. RESULTS: The 5-year overall survival (OS) of patients with CNG Stage I, II, and III was 97.0 %, 91.4 %, and 72.1 %, and survival curves of different stage groups were well-separated (all p < 0.001). The OS curves for 7th and 8th Stage I, II, and III almost overlapped. In patients with pre-treatment plasma EBV DNA > 0 and ≥ 1000 copies/ml, overall and inter-group OS differences were observed in CNG stage, while not shown in 7th and 8th stages. Among CNG Stage I, II, and III, the proportion of patients with EBV DNA = 0 was gradually decreasing (30.9 % vs 10.8 % vs 3.4 %), while the proportion of EBV DNA ≥ 1000 was gradually increasing (33.3 % vs 60.0 % vs 84.8 %, p < 0.001). CONCLUSIONS: The CNG staging system presents a more accurate segregation of survival rates than the 7th and 8th editions, and it is well aligned with EBV DNA. Further studies of the staging system are warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zheng S, Liu Y, He Z, et al. CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era. Radiother Oncol. 2025. PMID: 40692079. doi:10.1016/j.radonc.2025.111051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。